Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose exemestane after progression on standard-dose exemestane in advanced breast cancer
2008-004169-25Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exemestane in breast cancer, sponsored by European Institute of Oncology. Primary endpoint: Clinical benefit rate. Started Jan 2009; status: terminated.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-004169-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004169-25.